ATE157261T1 - Warte-effekt bei tumorzerstörender therapie - Google Patents

Warte-effekt bei tumorzerstörender therapie

Info

Publication number
ATE157261T1
ATE157261T1 AT93910880T AT93910880T ATE157261T1 AT E157261 T1 ATE157261 T1 AT E157261T1 AT 93910880 T AT93910880 T AT 93910880T AT 93910880 T AT93910880 T AT 93910880T AT E157261 T1 ATE157261 T1 AT E157261T1
Authority
AT
Austria
Prior art keywords
tumor
replication
transformed
competent
treatment
Prior art date
Application number
AT93910880T
Other languages
English (en)
Inventor
Kenneth W Culver
R Michael Blaese
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE157261T1 publication Critical patent/ATE157261T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AT93910880T 1992-05-01 1993-05-03 Warte-effekt bei tumorzerstörender therapie ATE157261T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87751992A 1992-05-01 1992-05-01

Publications (1)

Publication Number Publication Date
ATE157261T1 true ATE157261T1 (de) 1997-09-15

Family

ID=25370142

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93910880T ATE157261T1 (de) 1992-05-01 1993-05-03 Warte-effekt bei tumorzerstörender therapie

Country Status (11)

Country Link
US (1) US6045789A (de)
EP (1) EP0637966B1 (de)
JP (1) JPH07506370A (de)
AT (1) ATE157261T1 (de)
AU (1) AU675948B2 (de)
CA (1) CA2134763A1 (de)
DE (1) DE69313443T2 (de)
DK (1) DK0637966T3 (de)
ES (1) ES2110091T3 (de)
GR (1) GR3025493T3 (de)
WO (1) WO1993021959A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063652A1 (en) * 1988-03-21 2004-04-01 Jolly Douglas J. Combination gene delivery vehicles
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
US6555370B1 (en) 1990-11-13 2003-04-29 Immunex Corporation Bifunctional selectable fusion genes
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
FR2699082B1 (fr) * 1993-02-22 1995-05-05 Pasteur Institut Composition pour le traitement de tumeurs et l'immunisation d'organismes à l'encontre de tumeurs.
AU6953394A (en) * 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
WO1995009655A1 (en) * 1993-10-06 1995-04-13 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Treatment of tumors by genetic transformation of tumor cells with genes encoding negative selective markers and cytokines
FI954602L (fi) * 1993-11-18 1996-03-18 Viagene Inc Koostumukset ja menetelmät käyttää ehdollisesti letaaleja geenejä
US5877010A (en) * 1994-05-02 1999-03-02 University Of Washington Thymidine kinase mutants
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
DE4431401A1 (de) 1994-08-24 1996-02-29 Max Delbrueck Centrum Lebendvakzine gegen Tumorerkrankungen
JP3822261B2 (ja) * 1994-09-09 2006-09-13 財団法人癌研究会 癌の遺伝子治療剤
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique
US20020115213A1 (en) * 1998-08-14 2002-08-22 Northeastern Ohio Universities Of Medicine Engraftable neural progenitor & stem cells for brain tumor therapy
US7005126B1 (en) * 1999-06-08 2006-02-28 Human Gene Therapy Research Institute Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect
DE19928342A1 (de) * 1999-06-21 2000-12-28 Deutsches Krebsforsch Vektoren zur gentherapeutischen Tumorbehandlung
KR100601982B1 (ko) 2005-01-20 2006-07-18 삼성전자주식회사 흡열반응을 통한 가열-냉각 과정에 의한 세포 용해 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007936A1 (en) * 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
CA2051288C (en) * 1990-09-14 2002-02-05 Robert L. Martuza Viral targeted destruction of neoplastic cells
ES2080341T3 (es) * 1990-09-14 1996-02-01 Univ Johns Hopkins Metodos y composiciones para la terapia genetica y la potenciacion de la inmunidad antitumoral.
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
JPH06509578A (ja) * 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5529774A (en) * 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
AU663725B2 (en) * 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract

Also Published As

Publication number Publication date
WO1993021959A1 (en) 1993-11-11
AU4221793A (en) 1993-11-29
AU675948B2 (en) 1997-02-27
ES2110091T3 (es) 1998-02-01
GR3025493T3 (en) 1998-02-27
DK0637966T3 (da) 1998-05-04
CA2134763A1 (en) 1993-11-11
EP0637966B1 (de) 1997-08-27
US6045789A (en) 2000-04-04
EP0637966A1 (de) 1995-02-15
DE69313443T2 (de) 1998-03-19
JPH07506370A (ja) 1995-07-13
DE69313443D1 (de) 1997-10-02

Similar Documents

Publication Publication Date Title
ATE157261T1 (de) Warte-effekt bei tumorzerstörender therapie
DK0584266T3 (da) Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf
EP0232968A3 (en) Apparatus and method for sustaining vitality of organs of the gastrointestinal tract
CA2190628A1 (en) An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
CA2190624A1 (en) An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
AU588806B2 (en) Drug, and methods of preparing and using it for treatment of tumors
FI914427A0 (fi) Expression av exogena polynukleotid- sekvenser i ett ryggradsdjur.
PH25590A (en) Active specific immune suppression
JPS6470415A (en) Skin permeable remedy system
NO975730L (no) Metode for ökning av beskyttende immunresponser
NO875252D0 (no) Fremgangsmaate og system for behandling av partikkelboreslam.
GB8630071D0 (en) Medicaments
CA2118724A1 (en) Detection method for c-raf-1 genes
EP0057209A4 (de) Neue aminosäurezusammensetzung sowie therapie zur behandlung von stress und wunden.
AU4908385A (en) Priming and purging blood treatment apparatus
EP0180737A3 (en) Use of preparations containing gamma-interferon (ifn-gamma) for treating rheumatic diseases
EP0345356A4 (en) Platinum complex and therapeutic agent for malignant tumor
Lotan et al. Suppression of the Transformed Cell Phenotype Expression by
SE8804607L (sv) Vattenformuleringar innehaallande ett piperidinylcyklopentylheptenonsyraderivat
DE3374066D1 (en) N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor
IT8721683A0 (it) Procedimento per la reidratazione rapida di legumi e simili, nonche'apparecchiatura per la reidratazione rapida ed in continuov di legumi e simili.
DE3166503D1 (en) 1,5-bis-(1,4-benzodioxin-2-yl)-3-azapentane-1,5 diols, process for their preparation, pharmaceutical preparations containing them and their therapeutical use
GR3005716T3 (de)
ZA887365B (en) Adheson variants
EP0341318A4 (en) Novel platinum (ii) complex, process for preparing the same, and therapeutic agent for malignant tumor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee